This research study is studying a drug DAY101 (formerly TAK-580, MLN2480) as a possible
treatment a low-grade glioma that has not responded to other treatments.
The name of the study drug involved in this study is:
• DAY101 (formerly TAK-580, MLN2480)
Phase:
Phase 1
Details
Lead Sponsor:
Karen D. Wright MD
Collaborators:
Day One Biopharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI) Pacific Pediatric Neuro-Oncology Consortium PLGA Foundation PLGA Fund at Pediatric Brain Tumor Foundation Team Jack Foundation